The strong revenue growth trajectory and key milestones (CPT code, FDA inspection, Nasdaq listing) support the bullish narrative, but the company is still early-stage with a $42M market cap. Monitor Q3 2026 results for continued revenue acceleration and progress on U.S. reimbursement adoption post-CPT code activation in January 2027.
Price Chart
Executive Summary
QT Imaging issued a mid-year 2026 letter to shareholders highlighting strong H1 2026 revenue of $14.0M (+116% YoY), 28 scanners shipped (double H1 2025), and FY 2026 revenue guidance of ~$39M. The company also completed a $10M public offering, extended debt maturity, returned to Nasdaq, and secured a Category III CPT code effective Jan 2027. While the revenue growth is impressive from a low base, the company remains a small-cap growth-stage medtech with a $42M market cap, and the filing is a forward-looking update with no new hard financial data beyond what was previously announced.
Key Facts
- H1 2026 revenue of $14.0M, up 116% YoY from H1 2025
- Shipped 28 Breast Acoustic CT scanners in H1 2026, double H1 2025
- FY 2026 revenue guidance of approximately $39M
- Completed $10M underwritten public offering in Q2 2026
- Extended senior secured term loan maturity to March 31, 2029
- Cash and restricted cash of approximately $14.2M as of August 7, 2026
- Returned to Nasdaq Capital Market and added to Russell Microcap Index
- AMA approved Category III CPT code for 3D quantitative transmission volumetric ultrasound tomography, effective Jan 1, 2027
- Completed first routine FDA inspection with zero Form 483 observations
- Relocating to a 22,000 sq ft facility in Petaluma, CA, reducing lease cost per sq ft by ~55%
Financial Impact
H1 2026 revenue $14.0M (+116% YoY); FY 2026 guidance ~$39M; cash position ~$14.2M; $10M public offering completed
Risk Factors
- Growth-stage medtech with limited operating history and $42M market cap
- Geopolitical risks in Gulf region impacting international commercial activities
- Dependence on successful U.S. reimbursement adoption post-CPT code activation in 2027
- Forward-looking guidance of ~$39M may be subject to execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-057548 |
| Document: qti-20260818.htm | 0001628280-26-057548 |
| Document: 0001628280-26-057548-index-headers.html | 0001628280-26-057548 |
| Document: 0001628280-26-057548-index.html | 0001628280-26-057548 |
| Document: 0001628280-26-057548.txt | 0001628280-26-057548 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 8w ago | 8-K | $2.77 $2.55 | ▼ −8.12% | ▼ −8.44% | $2.30 (−16.97%) |
Aug 18, 2026 9w ago | 8-K | $2.91 $2.69 | ▼ −7.56% | ▼ −6.57% | $2.30 (−20.96%) |
Jul 28, 2026 12w ago | 8-K | $2.71 $3.17 | ▲ +16.97% | ▲ +11.95% | $2.30 (−15.13%) |
Feb 25, 2026 34w ago | 8-K | $5.50 $6.30 | ▲ +14.55% | ▲ +20.96% | $2.30 (−58.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers